Clément S
Plateau technique de production des PSL, EFS Rhône-Alpes, 1390, rue Centrale, 01708 Beynost, France.
Transfus Clin Biol. 2011 Apr;18(2):250-61. doi: 10.1016/j.tracli.2011.02.022. Epub 2011 Apr 6.
Labile blood products are obtained from samples of whole blood or aphaeresis. The techniques of preparation evolve with technological advances, which allow both an increasing automation and an intensification of the sanitary safety of the blood products. Over the last ten years, thanks to the availability of new technologies, several measures have been introduced in order to reduce the risk of transmission of pathogens and prevent the onset of transfusion-related acute lung injury (TRALI): leukoreduction, use of platelet storage solutions, inactivation of plasma and presumably of platelets in a very near future. The control of transfusion risk also depends on proper use of labile blood products. To assist the prescriber in his treatment options and to standardize practices, the French Agency for Sanitary Safety of Health Products has issued recommendations in terms of utilization of blood products that are detailed in this review of major labile blood products available.
不稳定血液制品是从全血样本或单采血液成分中获得的。其制备技术随着技术进步而不断发展，这使得血液制品的自动化程度不断提高，卫生安全性也得到加强。在过去十年中，由于新技术的出现，已采取了多项措施来降低病原体传播风险，并预防输血相关急性肺损伤（TRALI）的发生：白细胞滤除、使用血小板保存液、血浆灭活以及在不久的将来可能对血小板进行灭活。输血风险的控制还取决于不稳定血液制品的正确使用。为了协助开处方者选择治疗方案并规范操作，法国卫生产品卫生安全局已发布了关于血液制品使用的建议，这些建议在本次对现有主要不稳定血液制品的综述中进行了详细阐述。
